ArticlePloS one2014
On the perplexingly low rate of transport of IgG2 across the human placenta.
Article in PloS one, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 37 citations in OpenAlex.
- Maternal inflammation disrupts transplacental antibody transfer in pregnant individuals with and without HIV.Frontiers in immunology · 2026Article
- A literature review of drug transport mechanisms during lactation.CPT: pharmacometrics & systems pharmacology · 2024Review
- Review
- Diverging Maternal and Cord Antibody Functions From SARS-CoV-2 Infection and Vaccination in Pregnancy.The Journal of infectious diseases · 2024Article
- Immunomodulation of Antibody Glycosylation through the Placental Transfer.International journal of molecular sciences · 2023Review
- A Literature Review of Changes in Phase II Drug-Metabolizing Enzyme and Drug Transporter Expression during Pregnancy.Pharmaceutics · 2023Review
- Article
- Vaccination in Pregnancy against Pertussis: A Consensus Statement on Behalf of the Global Pertussis Initiative.Vaccines · 2022Review
- Exposure to perfluoroalkyl substances and neonatal immunoglobulin profiles in the upstate KIDS study (2008-2010).Environmental pollution (Barking, Essex : 1987) · 2022Article
- Human IgE does not bind to human FcRn.Scientific reports · 2022Article
- Age-dependent nasal immune responses in non-hospitalized bronchiolitis children.Frontiers in immunology · 2022Article
- Evolution of protection after maternal immunization for respiratory syncytial virus in cotton rats.PLoS pathogens · 2021Article
- Colostrogenesis: Role and Mechanism of the Bovine Fc Receptor of the Neonate (FcRn).Journal of mammary gland biology and neoplasia · 2021Review
- Defective dystrophic thymus determines degenerative changes in skeletal muscle.Nature communications · 2021Article
- Placental disposition of eculizumab, C5 and C5-eculizumab in two pregnancies of a woman with paroxysmal nocturnal haemoglobinuria.British journal of clinical pharmacology · 2021Article
- Estrogen-Driven Changes in Immunoglobulin G Fc Glycosylation.Experientia supplementum (2012) · 2021Review
- FcRn, but not FcγRs, drives maternal-fetal transplacental transport of human IgG antibodies.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Update on Transplacental Transfer of IgG Subclasses: Impact of Maternal and Fetal Factors.Frontiers in immunology · 2020Article
- Maternal Immunization: Nature Meets Nurture.Frontiers in microbiology · 2020Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The neonatal receptor, FcRn, mediates both serum half-life extension as well as active transport of maternal IgG to the fetus during pregnancy. Therefore, transport efficiency and half-life go hand-in-hand. However, while the half-life of the human IgG2 subclass is comparable to IgG1, the placental transport of IgG2 is not, with the neonatal IgG1 levels generally exceeding maternal levels at birth, but not for IgG2. We hypothesized that the unique short-hinged structure of IgG2, which enables its κ-, but not λ-isotype to form at least three different structural isoforms, might be a contributing factor to these differences. To investigate whether there was any preference for either light chain, we measured placental transport of IgG subclasses as well as κ/λ-light chain isotypes of IgG1 and IgG2 in 27 matched mother-child pairs. We also studied the half-life of IgG1 and IgG2 light chain isotypes in mice, as well as that of synthesized IgG2 structural isotypes κA and κB. In order to investigate serum clearance of IgG1 and IgG2 light-chain isotypes in humans, we quantified the relative proportions of IgG1 and IgG2 light chains in hypogammaglobulinemia patients four weeks after IVIg infusion and compared to the original IVIg isotype composition. None of our results indicate any light chain preference in either of the FcRn mediated mechanisms; half-life extension or maternal transport.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.